Table 33Oxybutynin (pre vs post treatment) - Clinical study characteristics and clinical summary of findings

No. of studiesDesignTreatment (n)Control (n)ResultsLimitationsInconsistencyIndirectnessImprecisionOther considerationsQuality
Outcome: Continence
1 [A]ObservationalOxybutynin (41)-No. incontinent Before vs after 35/41 vs 11/35
RR 2.72 (1.64 to 4.50)
S (i)NNNNVery low
1 [B]Prospective open label trialOxybutynin (111)-% catheterisation without intermittent leaking accident Increase from baseline 21.5%; p<0.001S (i)NNN (iI)NVery low
1 [C]ObservationalOxybutynin (37)-Before vs after Regularly dry 1/37 vs 18/37
Always wet between micturations 18/37 vs 3/37
S (i)NNNNVery low
1 [D]ObservationalOxybutynin (35)-Virtually dry between catheterisations 25/35
Significant wetting 8/35
S (i)NNN (ii)NVery low
1 [E]ObservationalOxybutynin (13)-Mostly continent 5/13 Significant improvement 3/13 No improvement 5/13S (i)NNN (ii)NVery low
1 [F]ObservationalOxybutynin (30)-Of the 29 incontinent 3 achieved continence and 19 decreased use of padsS (i)NNN (ii)NVery low
Outcome Maximum cystometric capacity
1 [A]ObservationalOxybutynin (41)-Before vs after mean (SD) mL 141 (96) vs 197 (99); p<0.01 MD 56S (i)NNN (ii)NVery low
1 [G]ObservationalOxybutynin Oral (67)Intravesical (34)Before vs after mean (SD) mL oral 128 (107) vs 214 (110) MD 86
−49.26) Intravesical 132 (103) vs 226 (118) MD 94
S (i)NNN (ii)NVery low
1 [B]Prospective open label trialOxybutynin (111)-Before vs after mean (SD) mL 196.9 (122.3)) vs 260.5 (126.111.97) ; p<0.001 MD 63.6S (i)NNN (ii)NVery low
1 [E]ObservationalOxybutynin (13)-Increased capacity 10/13 mean increase 41% (range −24 to + 95%)S (i)NNN (ii)NVery low
1 [F]ObservationalOxybutynin (30)-Before vs after mean (SD) mL 209 (103) vs 282 (148); p<0.01 MD 73S (i)NNN (ii)NVery low
Outcome: Bladder compliance
1 [A]ObservationalOxybutynin (41)-Before vs after mean (SD) mL/cmH20 6.5 (5.6) vs 16.8 (13.7); p<0.01 MD 10.3S (i)NNN (iI)NVery low
1 [G]ObservationalOxybutynin Oral (67)Intravesical (34)Before vs after mean (SD) mL/cmH20 Oral 8.1 (6.3) vs 14.8 (11.6) MD 6.7 Intravesical 8.5 (6.1) vs 16.0 (11.0) MD 7.5S (i)NNN (iI)NVery low
1 [E]ObservationalOxybutynin (13)-Improved compliance 12/13S (i)NNN (ii)NVery low
Outcome: Adverse events (side effects)
1 [A]ObservationalOxybutynin (41)-13/41S (i)NNN (ii)NVery low
1 [C]ObservationalOxybutynin (39)-2/39S (i)NNN (ii)NVery low
1 [D]ObservationalOxybutynin (35)-2/35S (i)NNN (ii)NVery low
1 [F]ObservationalOxybutynin (30)-0/30S (i)NNN (ii)NVery low
Outcome: Urinary tract infections (UTI)
1 [G]ObservationalOxybutynin Oral (67)Intravesical (34)Experienced a decrease 70/101S (i)NNN (ii)NVery low
1 [C]ObservationalOxybutynin (33)-Before vs after Asymptomatic bacteriuria 10/33 vs 14/33 Lower UTI 11/33 vs 21/33 Upper UTI 9/33 vs 8/33 Use of prophylactic antibiotics 15/33 vs 15/33S (i)NNN (ii)NVery low
1 [D]ObservationalOxybutynin (35)Observation (13)Treament vs observation Gp UTI 2/35 vs 0/13 asymptomatic bacteriuria 21/35 vs 0/13NNNN (ii)NVery low
Outcome: Treatment adherence (Discontinuations)
1 [G]ObservationalOxybutynin Oral (67)Intravesical (34)Oral 11/67 Intravesical 6/34S (i)NNN (ii)NVery low
1 [C]ObservationalOxybutynin (39)-7/39S (i)NNN(ii)NVery low
1 [D]ObservationalOxybutynin (35)-2/35S (i)NNN (ii)NVery low
1 [E]ObservationalOxybutynin (28)-15/28S (i)NNN (ii)NVery low
1 [H]ObservationalOxybutynin (23)-15/23S (i)NNN (ii)NVery low

S serious N none RR relative risk MD mean difference CI confidence interval

i

Before vs after data

ii

Imprecision could not be assessed, data at high risk of bias

[A]

Goessl et al. (1998)53

[B]

Franco et al. (2005)52

[C]

Amark et al. (1998)61

[D]

Baskin et al. (1990)49

[E]

Connor et al. (1994)50

[F]

Painter et al. (1996)57

[G]

Ferrara et al. (2001)51

[H]

Palmer et al. (1997)58

From: 8, Treatment to improve bladder storage

Cover of Urinary Incontinence in Neurological Disease
Urinary Incontinence in Neurological Disease: Management of Lower Urinary Tract Dysfunction in Neurological Disease.
NICE Clinical Guidelines, No. 148.
National Clinical Guideline Centre (UK).
Copyright © 2012, National Clinical Guideline Centre.

Apart from any fair dealing for the purposes of research or private study, criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

The rights of National Clinical Guideline Centre to be identified as Author of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.